JKE-1674 是口服有效的谷胱甘肽过氧化物酶 4 (GPX4)抑制剂，是ML-210的活性代谢物，ML-210也是GPX4抑制剂。它可转换成丁腈氧化物 JKE-1777。它用与 ML-210 相同的方式杀死 LOX-IMVI 细胞，并被Ferroptosis抑制剂完全挽救。

JKE-1674 is an inhibitor of glutathione peroxidase 4 (GPX4). JKE-1674 is an active metabolite of the GPX4 inhibitor ML-210.

JKE-1674 reduces the viability of LOX-IMVI cancer cells with an EC50 of 0.03 μM and in a panel of additional cancer cell lines. JKE-1674 is completely rescued by ferroptosis inhibitors[1].

JKE-1674 (50?mg/kg; p.o.) could be detected in the serum of mice dosed orally with the compound[2].

2421119-60-8

C20H20Cl2N4O4

451.3

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years